(3,4-dichlorobenzyl)piperidine hydrochloride | 1171138-69-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (3,4-dichlorobenzyl)piperidine hydrochloride
• 英文别名: 4-(3,4-dichloro-benzyl)-piperidine hydrochloride；4-(3,4-Dichlorobenzyl)piperidine hydrochloride；4-[(3,4-dichlorophenyl)methyl]piperidine;hydrochloride
• CAS: 1171138-69-4
• 化学式: C₁₂H₁₅Cl₂N*ClH
• 分子量: 280.625
• InChiKey: QMXPLRLXVBJVNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.96
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (3,4-dichlorobenzyl)piperidine hydrochloride 在 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 4-(3,4-二氯苄基)哌啶盐酸盐
  参考文献：
  名称：

  5-MEMBERED HETEROARYL DERIVATIVE CONTAINING AT LEAST ONE N, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDERS, CONTAINING SAME AS ACTIVE INGREDIENT

  摘要：

  本发明涉及一种含有氮原子的五元杂环芳基衍生物，及其作为活性成分用于预防或治疗精神障碍的药物组合物，其中所述衍生物在5-羟色胺、去甲肾上腺素和多巴胺的三重再摄取抑制效果上表现出优异性能，因此在治疗精神障碍中具有实用性。

  公开号：

  EP4159726A1

文献信息

• [EN] HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] MODULATEURS D'URÉE SUBSTITUÉS PAR HÉTÉROARYLE D'AMIDE D'ACIDE GRAS HYDROLASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010068453A1

  公开（公告）日：2010-06-17

  Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

  描述了某些杂环取代的哌啶基和哌嗪基脲化合物，这些化合物可用作FAAH抑制剂。这些化合物可用于制备药物组合物，并用于治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、紊乱和症状，如焦虑、疼痛、炎症、睡眠障碍、进食障碍、胰岛素抵抗、糖尿病、骨质疏松症和运动障碍（例如多发性硬化）。
• HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE
  申请人：Breitenbucher J. Guy

  公开号：US20110237596A1

  公开（公告）日：2011-09-29

  Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

  本文描述了某些异杂环取代的哌啶基和哌嗪基脲化合物，这些化合物可用作FAAH抑制剂。此类化合物可用于制备药物组合物和治疗疾病状态、紊乱和由脂肪酸酰胺水解酶（FAAH）活性介导的情况的方法，例如焦虑、疼痛、炎症、睡眠障碍、进食障碍、胰岛素抵抗、糖尿病、骨质疏松症和运动障碍（例如多发性硬化症）。
• SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20150111922A1

  公开（公告）日：2015-04-23

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof: (I) in which m, n, W, X, Y, Z, R 1 , R 2 , R 3 and R 4 are as defined in the specification, for use in the treatment or prevention of a diseases o conition mediated by a prokineticin, such as psychiatric and neurological conditions.

  本发明提供了公式（I）的化合物及其药学上可接受的盐：（I）其中m、n、W、X、Y、Z、R1、R2、R3和R4如规范中所定义，用于治疗或预防由前动力素介导的疾病或情况，例如精神和神经疾病。
• THERAPEUTIC COMPOUNDS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20130324576A1

  公开（公告）日：2013-12-05

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R, R 1 , R 2 , R 3 and R 4 are as defined in the specification, for use in therapy.

  本发明提供公式（I）的化合物及其药学上可接受的盐，其中m、n、W、X、Y、Z、R、R1、R2、R3和R4在规范中定义，用于治疗。
• 이미다졸 유레아계 화합물 및 이를 포함하는 사이토크롬Ｐ450 활성 저해제
  申请人：SK Biopharmaceuticals Co., Ltd. 에스케이바이오팜 주식회사(120110188071) Corp. No ▼ 110111-4570720

  公开号：KR101496435B1

  公开（公告）日：2015-03-03

  본 발명은 인체 대사효소 활성의 측정 및 약물 상호작용에 대한 검색을 수행하기 위한 실험에서 사용될 수 있는 사이토크롬 P450(CYP450)저해 효과를 갖는 화합물에 관한 것이다. 보다 상세하게, 본 발명은 하기 화학식 (1)로 표현되는 이미다졸 유레아계 화합물 및 이를 포함하는 사이토크롬 P450 활성 저해 효과 검증용 시약에 관한 것이다. 화학식 (1) 상기 식에서, Ar은 치환되지 않거나, 할로겐, 탄소원자가 1-6인 직쇄 혹은 분쇄 알콕시 및 트리플루오로메틸로 구성되는 그룹으로부터 선택되는 하나 이상의 동일하거나 상이한 치환체로 치환될 수 있는 페닐 및 피리딘으로 구성되는 그룹으로부터 선택되며; l은 0, 1 또는 2이며; m은 1또는 2이며; 그리고 n은 1 또는 2이다. 약물 대사효소의 활성을 측정하기 위해서는 각 동종효소의 기질 약물을 사용하여 단독으로 측정하거나 동시에 배양하여 처리하는 칵테일 기법이 사용되는데, 이 과정에서 사용되는 사이토크롬 P450 각 동종효소의 여러 가지 저해제를 대신하여 5가지 동종효소를 모두 저해하는 본 발명의 이미다졸 유레아계 화합물을 사용하면 신약 개발 및 약물 상호작용 검색에 소요되는 시간과 경비를 줄일 수 있다. 사이토크롬 P450 CYP450 이미다졸 유레아계 시약 약물 상호작용

  This invention relates to compounds that have cytochrome P450 (CYP450) inhibitory effects which can be used in experiments to measure human metabolic enzyme activity and drug interactions. Specifically, the invention relates to imidazole urea compounds represented by chemical formula (1) and reagents for verifying cytochrome P450 activity inhibition that include these compounds. In formula (1), Ar is a group composed of phenyl and pyridine, which can be substituted with one or more identical or different substituents selected from an unsubstituted group, halogen, a group composed of 1-6 carbon atoms, or an alkoxy and trifluoromethyl group; l is 0, 1, or 2; m is 1 or 2; and n is 1 or 2. To measure the activity of drug-metabolizing enzymes, a cocktail technique is used to measure each enzyme substrate drug alone or in combination with culture treatment. By using the imidazole urea compound of the present invention, which inhibits all five cytochrome P450 enzymes instead of various inhibitors for each enzyme, the time and cost required for drug development and drug interaction screening can be reduced.